Interview Summary

Application No.

Applicant(s)

09/527,352

LeCruse et al.

Examiner

Vera Afremova

Art Unit **1651**

All participants (applicant, applicant's representative, PTO	personnel):
(1) Vera Afremova	(3) him Drawen
(2) Jon Weber	(4) Xingnon Lill
(1) Vera Afremova (2) Jon Weber Date of Interview	(5) Irles A. Taylon
Type: a) X Telephonic b) \(\bigcirc \) Video Conference c) \(\bigcirc \) Personal [copy is given to 1) \(\bigcirc \) applicant	
Exhibit shown or demonstration conducted: d) Yes	e) X No. If yes, brief description:
Claim(s) discussed: all	
Identification of prior art discussed:	
Agreement with respect to the claims f) was reached.	. g) \mathbf{X} was not reached. h) \mathbb{N} N/A.
Substance of Interview including description of the general any other comments:	nature of what was agreed to if an agreement was reached, or
Several issues have been discussed :	
1. The difference between BE (biliary index) and BC (biliary	clearance) appears to be based on calculations rather than on
	for detecting/measuring metabolism. {with regard to claims
	s a new matter because only one "reference" such as "protein EE] teaches normalization to "total substrata" (with regard to
claim 1, in particular, also 13, 39-66}.	(see astached ->)
	dments which the examiner agreed would render the claims copy of the amendments that would render the claims allowable is
i) It is not necessary for applicant to provide a separ	rate record of the substance of the interview (if box is checked).
Unless the paragraph above has been checked, THE FORM, INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPI already been filed, APPLICANT IS GIVEN ONE MONTH FROSUBSTANCE OF THE INTERVIEW. See Summary of Record	EP section 713.04). If a reply to the last Office action has DM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE
	V. M
Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.	Examiner's signature, if required

Attachment to interview summary

OG / 527, 352 invension 5/14/2002 date

Several issues have been discussed:

- 1. The difference between BE (biliary index) and BC (biliary clearance) appears to be based on calculations rather than on measuring different parameters or using different methods for detecting/measuring metabolism. {with regard to claims 39-66).
- 2. The concept of "normalizing" to a generic "reference" is a new matter because only one "reference" such as "protein content" is disclosed (page 30, line 29). The prior art {ref. EE] teaches an idea of normalization to a "total substrate" (with regard to claim 1, in particular, also 13, 39-66).
- 3. The claimed method (25-38) does not indicate the link between "candidate" compound and "marker" compound. The criticality between "simultaneously" and sequentially, for example, is uncertain. The teaching of ref. EE should/might be revaluated with regard to "extra cellular" markers as disclosed. The teaching of ref. EE should/might be reevaluated with regard to the uptake of two compounds such as, for example: "taurocholate" and "enkephalin" or the other two, for example: "morphine and salicylate. Are they "candidate" and "markers"?